Do Mylan shareholders want the CEO to keep raising the price of the EpiPen?

Do Mylan shareholders want the CEO to keep raising the price of the EpiPen? We don’t know yet. Investors like a company to deliver positive earning results and increased guidance, and the recent negative public opinion has given investors a reason to sell, which was what happened. Currently $MYL is in “oversold” territory. Mylan 1 […]

Source: NAKEDMEDICINE.COM - October 30, 2016 Category: Consumer Health News Authors: Jane Tags: Business of Medicine Source Type: blogs